Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
79 hedge funds and large institutions have $166M invested in Cascadian Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 8 closing their positions.
74% more call options, than puts
Call options by funds: $164K | Put options by funds: $94K
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
7% more capital invested
Capital invested by funds: $155M → $166M (+$11.1M)
4% more funds holding
Funds holding: 76 → 79 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.74M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.58M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$956K |
| 4 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$918K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$6.76M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$3.65M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$557K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$173K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$95.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DADC
76
D.A. Davidson & Co
Great Falls,
Montana
| – | -$14K | -3,833 | Closed |
|
77
Simplex Trading
Chicago,
Illinois
| – | -$12.7K | -3,310 | -100% |
|
|
MAM
78
Meeder Asset Management
Dublin,
Ohio
| – | -$4K | -1,014 | Closed |
|
|
LC
79
Landaas & Company
Milwaukee,
Wisconsin
| – | +$126 | +33 | New |
|
CASC Hedge Fund Activity: Q3 2017 in Review
79 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q3 2017, worth a combined $166M — up 7.2% from $155M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CASC positions and 8 closed out — a net gain of 4 holders — while 24 added to existing stakes and 15 trimmed.
The largest buyer was Tekla Capital Management, opening a new position worth an estimated $1.74M. The largest seller was Redmile Group, cutting an estimated $6.76M.
- 79 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q3 2017, up from 76 in Q2 2017.
- Funds reported $166M of Cascadian Therapeutics, Inc. stock for Q3 2017, up 7.2% quarter-over-quarter.
- 12 funds opened new Cascadian Therapeutics, Inc. positions in Q3 2017 and 8 closed out, a net change of +4 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q3 2017 was Tekla Capital Management, an estimated $1.74M added.
- The largest Cascadian Therapeutics, Inc. seller in Q3 2017 was Redmile Group, an estimated $6.76M sold.
Based on aggregated 13F filings for Q3 2017.